CONMED (CNMD)
(Delayed Data from NYSE)
$68.63 USD
-1.37 (-1.96%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $68.59 -0.04 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
CNMD 68.63 -1.37(-1.96%)
Will CNMD be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CNMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNMD
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Conmed (CNMD) is a Strong Growth Stock
CNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Here's Why Conmed (CNMD) is a Strong Value Stock
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
Other News for CNMD
IHF: Healthcare Dashboard For December
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Conmed (CNMD) and Veeva Systems (VEEV)
CONMED declares $0.20 dividend
Conmed Corp (CNMD) Trading Down 3.4% on Nov 26
Conmed’s BioBrace Implant Shows Promise but Awaits Crucial Trial Results Amid Financial Considerations